Does Editas (EDIT) Have the Potential to Rally 51.55% as Wall Street Analysts Expect?Zacks Investment Research • 02/10/23
Editas Medicine (EDIT) Crossed Above the 50-Day Moving Average: What That Means for InvestorsZacks Investment Research • 01/30/23
Editas Medicine (EDIT) Crossed Above the 20-Day Moving Average: What That Means for InvestorsZacks Investment Research • 01/25/23
Wall Street Analysts Predict a 72.25% Upside in Editas (EDIT): Here's What You Should KnowZacks Investment Research • 01/25/23
Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas' iNK Cell Franchise and Related Gene Editing TechnologiesGlobeNewsWire • 01/19/23
Editas Medicine, Inc. (EDIT) Presents at 41st Annual J.P. Morgan Healthcare Conference (Transcript)Seeking Alpha • 01/11/23
Editas Medicine to Present at the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/04/23